Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 74.8% in September

Exicure, Inc. (NASDAQ:XCUR) saw a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 32,600 shares, a decrease of 74.8% from the August 31st total of 129,500 shares. Currently, 4.9% of the shares of the stock are short sold. Based on an average trading volume of 1,340,000 shares, the short-interest ratio is currently 0.0 days.

Exicure Price Performance

Shares of NASDAQ:XCUR opened at $3.70 on Wednesday. The firm has a 50 day simple moving average of $0.93 and a 200 day simple moving average of $0.39. The company has a market cap of $32.01 million, a price-to-earnings ratio of -2.43 and a beta of 1.24. Exicure has a one year low of $1.44 and a one year high of $6.00.

Exicure (NASDAQ:XCUR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Insider Transactions at Exicure

In other news, major shareholder Co. Ltd. Dgp purchased 237,223 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was bought at an average price of $3.00 per share, with a total value of $711,669.00. Following the acquisition, the insider now owns 849,223 shares in the company, valued at approximately $2,547,669. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.90% of the stock is currently owned by insiders.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.